Dissociation of C-Reactive Protein Localizes and Amplifies Inflammation: Evidence for a Direct Biological Role of C-Reactive Protein and Its Conformational Changes
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
C-reactive protein (CRP) is a member of the pentraxin superfamily that is widely recognized as a marker of inflammatory reactions and cardiovascular risk in humans. Recently, a growing body of data is emerging, which demonstrates that CRP is not only a marker of inflammation but also acts as a direct mediator of inflammatory reactions and the innate immune response. Here, we critically review the various lines of evidence supporting the concept of a pro-inflammatory "CRP system." The CRP system consists of a functionally inert circulating pentameric form (pCRP), which is transformed to its highly pro-inflammatory structural isoforms, pCRP* and ultimately to monomeric CRP (mCRP). While retaining an overall pentameric structure, pCRP* is structurally more relaxed than pCRP, thus exposing neoepitopes important for immune activation and complement fixation. Thereby, pCRP* shares its pro-inflammatory properties with the fully dissociated structural isoform mCRP. The dissociation of pCRP into its pro-inflammatory structural isoforms and thus activation of the CRP system occur on necrotic, apoptotic, and ischemic cells, regular β-sheet structures such as β-amyloid, the membranes of activated cells (e.g., platelets, monocytes, and endothelial cells), and/or the surface of microparticles, the latter by binding to phosphocholine. Both pCRP* and mCRP can cause activation of platelets, leukocytes, endothelial cells, and complement. The localization and deposition of these pro-inflammatory structural isoforms of CRP in inflamed tissue appear to be important mediators for a range of clinical conditions, including ischemia/reperfusion (I/R) injury of various organs, cardiovascular disease, transplant rejection, Alzheimer's disease, and age-related macular degeneration. These findings provide the impetus to tackle the vexing problem of innate immunity response by targeting CRP. Understanding the "activation process" of CRP will also likely allow the development of novel anti-inflammatory drugs, thereby providing potential new immunomodulatory therapeutics in a broad range of inflammatory diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674 · cited 1×
“Moreover, the large-scale JUPITER trial has shown that treating patients with asymptomatic elevations in CRP provides benefit in reducing the cardiovascular event rate and death (7).”
BackgroundInflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Toll-like receptors: critical proteins linking innate and acquired immunity
Akira, S., Takeda, K., & Kaisho, T. (2001) · Nature Immunology · doi:10.1038/90609 · Cited by 4,777 · cited 1×
“org June 2018 | Volume 9 | Article 1351 as heat shock proteins and ROS, heparin sulfate, or fibrinogen (76).”
BackgroundScheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125 · cited 1×
“Alzheimer’s disease represents the leading cause of dementia (87).”
BackgroundComplement factor H polymorphism and age-related macular degeneration
Edwards, A. O., Ritter, R., Abel, K. J., Manning, A., Panhuysen, C., & Farrer, L. A. (2005) · Science · doi:10.1126/science.1110189 · Cited by 2,449 · cited 1×
“This SNP involving the CFH gene is considered one of the most significant genetic risk factors for AMD development (97).”
BackgroundMyocardial ischemia-reperfusion injury: a neglected therapeutic target
Hausenloy, D. J., & Yellon, D. M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci62874 · Cited by 2,357 · cited 1×
“Indeed, experimental evidence suggests that up to 50% of the final infarct volume from myocardial infarction is due to reperfusion injury (59).”
BackgroundMasters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
Serological reactions in pneumonia with a non-protein somatic fraction of Pneumococcus
Tillett, W. S., & Francis, T. (1930) · Journal of Experimental Medicine · doi:10.1084/jem.52.4.561 · Cited by 1,482 · cited 9×
“Here, CRP binds to stimulated monocytes, which release pro-inflammatory microvesicles loaded with pCRP*, thus allowing binding of the complement factor C1q and ultimately causing complement activation.”
BackgroundInfluentialThe physiological structure of human C-reactive protein and its complex with phosphocholine
Thompson, D., Pepys, M. B., & Wood, S. P. (1999) · Structure · doi:10.1016/s0969-2126(99)80023-9 · Cited by 818 · cited 2×
“Phe-66 regulates hydrophobic interactions with the methyl group of PC, while Glu-81 interacts with the positively charged nitrogen (12).”
BackgroundA systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain
Wang, J., Gu, B. J., Masters, C. L., & Wang, Y.-J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.111 · Cited by 808
Targeting C-reactive protein for the treatment of cardiovascular disease.
Pepys, M. B., Hirschfield, G. M., Tennent, G. A., Ruth Gallimore, J., Kahan, M. C., Bellotti, V., Hawkins, P. N., Myers, R. M., Smith, M. D., Polara, A., et al. (2006) · Nature · doi:10.1038/nature04672 · Cited by 672 · cited 15×
“Therefore, while the administration of exogenous human CRP to rodents has afforded essential insights regarding CRP biology, it does not allow for in vivo mechanistic studies of CRP in chronic inflammatory conditions such as IRI, transplant rejection, atherosclerosis, or AMD.”
BackgroundInfluentialSeddon, J. M. (2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.6.774 · Cited by 354 · cited 6×
“These are important observations, given that these changes are observed in patients with AMD and are linked to the development of AMD (98, 99).”
BackgroundInfluentialSTAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6
Zhang, D., Sun, M., Samols, D., & Kushner, I. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.16.9503 · Cited by 309 · cited 4×
“This upregulation occurs via the transcriptional activation of the STAT3, C/EBP, and NF-κB pathways (33, 37, 38).”
BackgroundInfluentialRidker, P. M. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.04.028 · Cited by 290 · cited 1×
“In this regard, the role of CRP as a biomarker reflecting cardiovascular risk has received much attention (79, 80).”
BackgroundWood, J. A., Wood, P. L., Ryan, R., Graff-Radford, N. R., Pilapil, C., Robitaille, Y., & Quirion, R. (1993) · Brain Research · doi:10.1016/0006-8993(93)91327-o · Cited by 244
Ridker, P. M. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.119214 · Cited by 206
Slevin, M., Matou, S., Zeinolabediny, Y., Corpas, R., Weston, R., Liu, D., Boras, E., Di Napoli, M., Petcu, E., Sarroca, S., et al. (2015) · Scientific Reports · doi:10.1038/srep13281 · Cited by 115 · cited 3×
“These features correlate with structural changes, with mCRP-treated mice displaying enhanced p-Tau and p-β amyloid plaque production (93).”
BackgroundInfluentialSelf-citationStrang, F., Scheichl, A., Chen, Y., Wang, X., Htun, N., Bassler, N., Eisenhardt, S. U., Habersberger, J., & Peter, K. (2012) · Brain Pathology · doi:10.1111/j.1750-3639.2011.00539.x · Cited by 94
Self-citation
Cited by
C-reactive protein and implications in rheumatoid arthritis and associated comorbidities
Pope, J. E., & Choy, E. H. (2021) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2020.11.005 · Cited by 320
C-Reactive Protein and Cancer—Diagnostic and Therapeutic Insights
Hart, P. C., Rajab, I. M., Alebraheem, M., & Potempa, L. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.595835 · Cited by 275
Self-citationC-reactive protein: structure, function, regulation, and role in clinical diseases
Zhou, H.-H., Tang, Y.-L., Xu, T.-H., & Cheng, B. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1425168 · Cited by 162
Li, H.-Y., Tang, Z.-M., Wang, Z., Lv, J.-M., Liu, X.-L., Liang, Y.-L., Cheng, B., Gao, N., Ji, S.-R., & Wu, Y. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.09.003 · Cited by 39
Metadata
- Authors
- McFadyen, J. D., Kiefer, J., Braig, D., Loseff-Silver, J., Potempa, L. A., Eisenhardt, S. U., & Peter, K.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2018-06-12
- Volume
- 9
- Pages
- 1351-1351
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2805852128
- Cited by
- 152
- References
- 18
- FWCI
- 5.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.